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Recent trends in medical research are, for a smaller number of large research programmes,
developed to address the big questions rather than for large numbers of small projects. This is
a trend encouraged by research funding bodies and the research community. This trend
requires more collaboration between research groups and international cooperation, as well as
increased inter-disciplinary working. This has also promoted greater standardisation of
methods to produce comparable results as well as encouraging the use of common technical
terms to facilitate working across disciplines. Recent examples of this trend in leprosy
research are the TRIPOD trials,1 the Participation Scale programme,2 the SALSA
programme,3 IDEAL4 and the INFIR programme. This paper presents an overview of the
INFIR programme to illustrate a collaborative programme of research in leprosy describing
the background, funding, implementation and output.
INFIR is the ILEP Co-ordinated Programme of Research on Nerve Function Impairment
and Reactions in Leprosy. ILEP (International Federation of Anti-Leprosy Associations)
identified the need for more research to address the challenges of nerve function impairment
and reactions in leprosy at a working session in December 1997. An expert workshop was
convened in June 1998 with representatives from a range of related disciplines as well as field
representatives from the leprosy world. This workshop identified a number of priorities and
opportunities which were developed into a single proposal for a programme of coordinated
research. This proposal was presented to the ILEP meeting in December 1998 and funding was
approved from the Follereau Foundation of Luxembourg with support from LEPRA Health in
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Action and The Leprosy Mission International. The proposal involved a range of field centres,
field laboratories and Universities in several countries in Africa, Asia and South America.
There were four specific strands to the programme and an INFIR steering group was
established in February 1999 and Dr. Jo Colston was appointed as chair of the overall steering
group. The strands reflected the priorities that emerged from the workshop and one important
aspect of the overall steering function was to ensure standardisation of methods and
terminology across all four strands. The four strands of research were: a Cohort study to
investigate prediction, detection, and pathogenesis of NFI in new patients, trials of new
treatments for reactions, study of recurrent and late reactions, and studies of delay in
detection and start of treatment of leprosy.
Cohort Study to Investigate Prediction, Detection and Pathogenesis of NFI in New
Patients
The cohort study was primarily based in India and involved centres in Naini, Faizabad and
Delhi working with laboratories in Miraj and Hyderabad. The study recruited a cohort of
303 new MB leprosy patients and conducted a detailed baseline assessment which included
clinical (sensory and motor), neurological (sensory and motor nerve conduction,
dynamometry, vibration and thermal tests), biopsies (skin and nerve), and blood samples.
The cohort was followed up 4-weekly for one year, and 8-weekly for the 2nd year. This study
was an immense undertaking employing novel methods of neurological assessment that had
not been used together with clinical and serological assays in a coordinated way.5 The findings
produced included the setting of standards and describing of reference values for many
neurological functions previously unreported in leprosy.6 The programme has already
produced a series of important publications,7,8 with a number about to be published.9 It also
has created a bank of serological data, neurological data and tissues that are still being used
to address specific questions. The study has set a standard for cohort investigations of
neurological function and reactions in leprosy, created new standard methods and informed
new research.10 Important findings to date include validation that monofilaments and
voluntary muscle testing reflect neurophysiology, the fact that neurophysiological tests show
nerve damage to be much more widespread than is clinically apparent, and that nerve
conduction and temperature testing can detect nerve damage in a sub-clinical stage, often
weeks or months before such damage becomes detectable with current clinical methods. The
findings show that neurological function impairment and certain changes in serology improve
prediction of new events and help understand the pathogenesis, and that nerve function
improves during MDT. An important question to be addressed in a future prospective study is
whether sub-clinical neuropathy treated at diagnosis would reduce the risk of permanent
nerve damage at the end of treatment.
Trials of New Treatments for Reactions
The need for improved drug therapy of leprosy reactions had been identified as a research
need at the preliminary workshop. Azathioprine and cyclosporine A were then identified as
potential drugs that could be used to improve immunosupression or as alternative therapies
for patients who are non-responsive to steroid therapy. Azathioprine and cyclosporine are
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well established immunosuppressant with many years of clinical experience in their use, so
their side effect profiles are well established. They are also both out of patent and so are
potentially affordable second-line drugs. Studies were developed with local clinicians in
Nepal and Ethiopia. These were designed as phase two studies to examine tolerability and
feasibility. The study in which azathioprine was added to prednisolone showed that patients
who received an azathioprine and prednisolone combination had similar outcomes to patients
who received prednisolone alone.11 The study in which cyclosporine A replaced prednisolone
for part of the treatment showed that patients receiving the combination some evidence
of improved nerve function outcome.12 A clinical severity score was also developed
during this study.
The studies were important because they demonstrated the potential for these drugs in
the treatment of leprosy reactions. They also enabled the development of study protocols
and they gave clinicians experience in using these agents. A formal pharmacokinetic
comparison of generic Cn against the Sandoz preparation showed that the generic and
drug company preparations were equivalent. The data from these small studies has been
crucial in providing the platform on which to develop the larger, better powered studies of
azathioprine and cyclosporine treatments in leprosy reactions which are being conducted
in India and Ethiopia.
Study of Recurrent and Late Reactions
The research questions on late and recurrent reactions were posed by field staff who
recognised these as specific challenges in the management of people with leprosy. The issue
of late reactions is an increasing challenge as the duration of MDT is reduced making the
ability to predict which patient will develop late reactions and methods for promptly detecting
such late reactions important. The question of recurrent and repeated reactions stimulated
discussions that were finalised at a workshop associated with an ILA congress and the
conclusions were published which proposed standard definitions to facilitate research and
make findings between studies comparable.13
Studies of Delay in Detection and Start of Treatment of Leprosy
The final part of the programme focused on delay in diagnosis as it was recognised that a high
proportion of all patients with nerve function impairment had developed the nerve damage
prior to diagnosis. This generated a number of studies using both quantitative and qualitative
methods to address the problem in a range of countries including Bangladesh, Nepal, India,
Malawi, Brazil, and Paraguay.14 – 17 The findings demonstrated that there was no single
reason for delay and that the factors associated with delay varied between local settings. The
work resulted in the production of a guideline for field use in identifying the factors
associated with delay in diagnosis in the local context. This guideline has now been widely
disseminated (more than 2000 copies) and is available in a number of languages such as
Spanish and Portuguese, it is available from the ILEP website.18 This work is now very
relevant to the validation of new case detection and delay in detection in studying the rapid
declines in new case detection being observed in several countries.
W. C. S. Smith et al.126
Conclusions
INFIR has been a highly successful and a very productive research initiative which has
contributed to prevention of nerve function impairment and better treatment of reactions. This
approach to research is an important model of inter-disciplinary, collaborative research that
has focused on recognised priority areas for leprosy research. The approach has important
added value to research in exchange of expertise, research capacity strengthening, and the
development of standardised research methods ensuring comparability of results between
countries and research centres. It led to the formation of a collaborative network for research
on reactions and nerve damage in leprosy called ‘Synapse’. The approach has also helped
secure significant research funding for the key research priorities of nerve function
impairment and reactions. The INFIR findings have been used as the basis for generating new
research ideas and stimulating new programmes at a workshop in the Netherlands. This
workshop was co-organised by Synapse members and the Netherlands Leprosy Relief,
bringing together scientists, clinicians and other experts to discuss the current state-of-the-art
and outline proposals for further research. The resulting consensus report was published in
2007.19 At least one proposal (called TENLEP) has already been submitted for joint funding
to several ILEP partners. A similar model of a large multi-disciplinary, collaborative
research programme managed by a steering committee has been adopted by the IDEAL
project to develop new tests for early diagnosis and understand transmission. It is vital that
such endeavours are funded. The global leprosy strategy is based on the same methods
that have been used for over 25 years and it is important that new research findings and
evidence is generated to inform future strategies. A commitment to new research is vital in
leprosy to improve the quality of treatment for patients, to reduce the disability and
impairment associated with leprosy and to work towards the control and eventual eradication
of the disease.
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